Therapeutic drug monitoring and dose adaptation of cisplatin in a newborn with hepatoblastoma: a case report
- 19 June 2018
- journal article
- research article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 82 (2) , 361-365
Abstract
Chemotherapy dosing in neonates represents a major clinical challenge because of a lack of clinical pharmacology information in this patient population. In this study, we investigate the use of cisplatin dose adaptation based on therapeutic drug monitoring in a 2-week-old neonate with localized hepatoblastoma.Keywords
This publication has 11 references indexed in Scilit:
- Risk-stratified staging in paediatric hepatoblastoma: a unified analysis from the Children's Hepatic tumors International CollaborationThe Lancet Oncology, 2017
- Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimensCancer Chemotherapy and Pharmacology, 2016
- Carboplatin therapeutic monitoring in preterm and full-term neonatesEuropean Journal of Cancer, 2015
- Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma (SIOPEL-4): a prospective, single-arm, feasibility studyThe Lancet Oncology, 2013
- Functional Maturation of Drug Transporters in the Developing, Neonatal, and Postnatal KidneyMolecular Pharmacology, 2011
- Drug transporters of platinum-based anticancer agents and their clinical significanceDrug Resistance Updates, 2011
- Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk HepatoblastomaNew England Journal of Medicine, 2009
- Tissue distribution, ontogeny and induction of the transporters Multidrug and toxin extrusion (MATE) 1 and MATE2 mRNA expression levels in miceLife Sciences, 2008
- Hepatic Tumors in ChildrenClinics in Liver Disease, 2001
- Analysis of platinum in biological materials by flameless atomic absorption spectrophotometryBiochemical Medicine, 1977